Epigenomics Signs Distribution Deal with Pronto Diagnostics for Epi proColon in Israel
Epigenomics expands commercial reach for CE-marked product beyond home market
Epigenomics AG and Pronto Diagnostics Ltd. announced that they have signed an exclusive distributor agreement for the commercialization of Epigenomics’ Epi proColon test in Israel.
Epi proColon is the world’s first CE-marked molecular diagnostic test for the early detection of colorectal cancer in blood. The test is based on Epigenomics’ proprietary biomarker Septin9. Pronto Diagnostics expects to begin marketing the test in Israel in November 2010.
“Epi proColon facilitates the early detection for colorectal cancer making diagnosis easier and more patient-friendly than ever,” Dr. Nir Navot, Chief Executive Officer of Pronto Diagnostics explained. “This test can be performed along with other routine blood tests and does not require any preparation of the screened individual. We expect that a significantly higher number of people will be prepared to undergo screening for colorectal cancer with this new test than with current methods such as stool tests and colonoscopy alone.”
Epi proColon is currently marketed by Epigenomics directly in Germany, Austria and Switzerland. Outside this home market, it is Epigenomics’ strategy to make the CE-marked test broadly available through a mix of direct commercialization and a distributor network.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.